Search results
Results from the WOW.Com Content Network
The most common chemotherapy drug for prostate cancer is docetaxel (Taxotere), which is usually given with prednisone, a steroid medicine. After starting docetaxel, many men experience the improvements in disease-related symptoms, including pain, fatigue and loss of energy.
Docetaxel and cabazitaxel have been shown to help men live longer, on average, than older chemo drugs. They may shrink the cancer or slow its growth, and they may also reduce symptoms, resulting in a better quality of life. Still, chemo is very unlikely to cure prostate cancer.
Chemotherapy uses anti cancer drugs to destroy prostate cancer cells. The drugs circulate throughout the body in the bloodstream. The most common type of chemotherapy used for prostate cancer is docetaxel.
For continuous docetaxel therapy, docetaxel is continuously infused in every cycle until the disease eventually progresses. Currently, most studies about maximizing exposure to docetaxel in prostate cancer are based on intermittent docetaxel therapy. 8, 14–16
In this phase 3 study, two schedules of docetaxel administered with prednisone were compared with mitoxantrone plus prednisone, the standard chemotherapy for hormone-refractory prostate...
Docetaxel (Taxotere ®) is considered the standard of care in chemotherapy for prostate cancer that is resistant to hormone therapy. It works by damaging the structure of prostate cancer cells. Another chemotherapy drug for treating castration-resistant prostate cancer is cabazitaxel (Jevtana ®).
Taxane chemotherapy agents approved for the treatment of advanced prostate cancer include docetaxel (Taxotere®) and cabazitaxel (Jevtana®). As mentioned, docetaxel is also effective in prolonging life in patients who are starting hormone therapy for the first time for metastatic disease.
We assigned men with metastatic, hormone-sensitive prostate cancer to receive either ADT plus docetaxel (at a dose of 75 mg per square meter of body-surface area every 3 weeks for six cycles) or...
ADT–docetaxel–abiraterone–prednisone is recommended as first-line treatment for fit men with de novo metastatic hormone-sensitive prostate cancer (mHSPC), especially in those with multiple bone metastases (>3) or visceral metastases [I, B; European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) v1.1 score: 4 ...
Based on this updated long-term data, it appears that most of the benefit of adding docetaxel to AS + RT in men with high-risk prostate cancer is modest and observed earlier in the treatment...